Most-favoured-nation drug pricing · Senate · Apr 23, 2026 · 49–49
Most-favoured-nation drug prices
Share voting the stated Pharma and health care position (nay)
52%
$10K+: 47 of 91 covered members
vs
17%
Below $10K: 1 of 6 covered members
Compare within each recorded party
Democrats: $10K+ 0% (0/40); below $10K 0% (0/4).
Republicans: $10K+ 94% (47/50); below $10K 100% (1/1).
Independents: $10K+ 0% (0/1); below $10K 0% (0/1).
Party comes from Voteview’s member record for the roll call’s Congress and may not capture changes within that Congress. Party splits do not adjust for tenure, committee roles or the mix of selected votes. Small groups can produce unstable percentages.
$171K
average traced funding, with industry; 48 covered members
$130K
average traced funding, against industry; 49 covered members
0
voting members excluded for unavailable coverage
$10K+, voted with industry
- Roger Marshall$432K
- Tim Scott$399K
- John Curtis$379K
- Mitch McConnell$363K
- Bill Cassidy$348K
$10K+, voted against industry
- Lisa Blunt Rochester$645K
- Susan Collins$604K
- Ron Wyden$406K
- Charles Schumer$350K
- Catherine Cortez Masto$313K
A 2026 budget motion to peg US drug prices to what other rich countries pay. Tied 49–49, so it failed. This is a retrospective comparison. Funding includes covered 2020–2026 election cycles and may have arrived after the vote. It does not measure whether money changed a vote. 0 voting members excluded for unavailable coverage. Threshold: $10K in traced funding.
The full detail →